2018

1.

[1]

2.

- 2011

[2]

1

2

3 /

4 ≥5/Hp

/

. 2017 [3]

1.

2.

3.

4.

5.

2008 [4]

1.

2.

3.

4.

5.

1.

2. 15 1

3. 30 20 30-50
10-15

- 2011
[2]

1.

2.

3.

1.

2.

3.

[5] [6]

1.

2.

3.

( )

= - / × 100%

1. ≥ 95%

2. ≥ 70%

3. ≥ 30% ≤ 69%

4. ≤ 29%

1

	0	2	4	6
		10	10-15	15

		37.5~38	38.1~39	39

Commented [1]:

[1] , . [M]. ,2017.

[2] . : [M]. , 2009.

[3] , , . /
[C]. 2017 . 2017.

[4] . : [M].
, 2008.

[5] . ( )( )[M]. , 2008.

[6] . : [J]. , 2002.

~~2018~~

~~TCD :BNS020~~

~~ICD-10 N10.X01~~

~~1.~~

~~1~~

~~2 -~~

~~2011~~

~~2.~~

~~/~~

~~. 2017~~

~~2008~~

~~1.~~

~~2.~~

~~≤14~~

~~1.~~

~~2.~~

~~1.~~

~~CRP ESR~~

~~+~~

~~2.~~

~~N- -β NAG β2~~

~~24~~

~~G 1,3-β-D- GM( )~~

~~B B B X~~

~~CT~~

~~1.~~

~~1~~

~~2~~

~~3~~

~~4~~

~~5~~

~~2.~~

~~3.~~

~~1~~

~~2~~

~~4.~~

~~5.~~

~~6.~~

~~1.~~

~~2.~~

~~3. /~~

~~1.~~

~~2.~~

~~3.~~

~~TCD :BNS020 ICD-10 N10.X01~~

~~≤14~~

	~~1~~

I / I I

24

C

+

B

B

		~~□ B~~ ~~□ X~~
	~~□ □~~ ~~□ □~~ ~~□~~	
	~~□ □ :~~ ~~1.~~ ~~2.~~	

	~~2~~	~~3 7~~

	□ □ □ □ □ □ □	□ □ □ □
	□ □ I /II □ □ 24 □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ NAG β 2 □	□ □ I /II □ □ 24 □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □

			~~CT~~	
	~~☐~~ ~~☐~~ ~~☐~~ ~~☐~~		~~☐~~ ~~☐~~ ~~☐~~ ~~☐~~	
	~~☐ ☐ :~~ ~~1.~~ ~~2.~~		~~☐ ☐ :~~ ~~1.~~ ~~2.~~	

	~~8 13~~	~~14~~
	~~☐~~ ~~☐~~ ~~☐~~ ~~☐~~ ~~☐~~	~~☐~~ ~~☐~~ ~~☐~~ ~~☐~~ ~~☐~~ ~~☐~~

	□ □ 24		□ □	
	□ □ □ □		□ □ □ □ □	
	□ □ : 1. 2.		□ □ : 1. 2. □	